I

Investigative Clinical Research of Indiana, LLC | Noblesville, IN

Research site

(Unclaimed)

Location

111 Monument Circle, Indianapolis, Indiana, United States of America

Site insights

Top conditions

Top treatments

Dexamethasone

Gemcitabine

Elotuzumab

Carboplatin

Prednisone

Pegcetacoplan

Erlotinib

Pomalidomide

Melphalan

Xyrem®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 40 total trials

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL w...

Enrolling

Relapsed/refractory Diffuse Large B-cell Lymphoma

Drug: Selinexor (continuous therapy)

Drug: Gemcitabine (combination therapy)

Pegcetacoplan Long Term Safety and Efficacy Extension Study

This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.

Active, not recruiting

PNH

Drug: Pegcetacoplan

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling

Triple Negative Breast Cancer

Drug: Capecitabine

Drug: Sacituzumab govitecan-hziy (SG)